Ceftriaxone: Difference between revisions

Jump to navigation Jump to search
No edit summary
(No difference)

Revision as of 14:59, 14 April 2009

Ceftriaxone
Clinical data
Pregnancy
category
  • AU: B1
  • US: B (No risk in non-human studies)
Routes of
administration
Intravenous, intramuscular
ATC code
Legal status
Legal status
  • AU: S4 (Prescription only)
Pharmacokinetic data
Bioavailabilityn/a
MetabolismNegligible
Elimination half-life5.8–8.7 hours
Excretion33–67% renal, 35–45% biliary
Identifiers
CAS Number
PubChem CID
DrugBank
E number{{#property:P628}}
ECHA InfoCard{{#property:P2566}}Lua error in Module:EditAtWikidata at line 36: attempt to index field 'wikibase' (a nil value).
Chemical and physical data
FormulaC18H18N8O7S3
Molar mass554.58 g/mol

WikiDoc Resources for Ceftriaxone

Articles

Most recent articles on Ceftriaxone

Most cited articles on Ceftriaxone

Review articles on Ceftriaxone

Articles on Ceftriaxone in N Eng J Med, Lancet, BMJ

Media

Powerpoint slides on Ceftriaxone

Images of Ceftriaxone

Photos of Ceftriaxone

Podcasts & MP3s on Ceftriaxone

Videos on Ceftriaxone

Evidence Based Medicine

Cochrane Collaboration on Ceftriaxone

Bandolier on Ceftriaxone

TRIP on Ceftriaxone

Clinical Trials

Ongoing Trials on Ceftriaxone at Clinical Trials.gov

Trial results on Ceftriaxone

Clinical Trials on Ceftriaxone at Google

Guidelines / Policies / Govt

US National Guidelines Clearinghouse on Ceftriaxone

NICE Guidance on Ceftriaxone

NHS PRODIGY Guidance

FDA on Ceftriaxone

CDC on Ceftriaxone

Books

Books on Ceftriaxone

News

Ceftriaxone in the news

Be alerted to news on Ceftriaxone

News trends on Ceftriaxone

Commentary

Blogs on Ceftriaxone

Definitions

Definitions of Ceftriaxone

Patient Resources / Community

Patient resources on Ceftriaxone

Discussion groups on Ceftriaxone

Patient Handouts on Ceftriaxone

Directions to Hospitals Treating Ceftriaxone

Risk calculators and risk factors for Ceftriaxone

Healthcare Provider Resources

Symptoms of Ceftriaxone

Causes & Risk Factors for Ceftriaxone

Diagnostic studies for Ceftriaxone

Treatment of Ceftriaxone

Continuing Medical Education (CME)

CME Programs on Ceftriaxone

International

Ceftriaxone en Espanol

Ceftriaxone en Francais

Business

Ceftriaxone in the Marketplace

Patents on Ceftriaxone

Experimental / Informatics

List of terms related to Ceftriaxone

Please Take Over This Page and Apply to be Editor-In-Chief for this topic: There can be one or more than one Editor-In-Chief. You may also apply to be an Associate Editor-In-Chief of one of the subtopics below. Please mail us [1] to indicate your interest in serving either as an Editor-In-Chief of the entire topic or as an Associate Editor-In-Chief for a subtopic. Please be sure to attach your CV and or biographical sketch.

Ceftriaxone (INN) (IPA: Template:IPA) is a third-generation cephalosporin antibiotic. Like other third-generation cephalosporins, it has broad spectrum activity against Gram positive and Gram negative bacteria. In most cases, it is considered to be equivalent to cefotaxime in terms of safety and efficacy. Ceftriaxone sodium is marketed by Hoffman-La Roche under the trade name Rocephin.

Clinical use

Ceftriaxone is often used (in combination, but not direct, with macrolide and/or aminoglycoside antibiotics) for the treatment of community-acquired pneumonia. It is also a choice drug for treatment of bacterial meningitis. In pediatrics, it is commonly used in febrile infants between 4 and 8 weeks of age who are admitted to the hospital to exclude sepsis. It has also been used in the treatment of Lyme disease and gonorrhea.

The usual starting dose is 1 gram IV daily although dosage may be adjusted for body mass in younger patients. Doses range from 1–2 grams IV or IM every 12–24 hours, depending on the type and severity or the infection, up to 4 grams daily. For gonorrhoea the usual adult dose is a single intramuscular injection of 125 mg. Patients treated for gonorrhoea are usually also treated for chlamydia, often with azithromycin. The injection is unusually painful and therefore administered with lidocaine as a local anesthetic. However, individuals who are allergic to lidocaine can expect approximately 1 hour of pain, similar to being forcefully kicked or punched in the site of injection (usually the buttocks). It is not a stinging or burning pain, and it is very intense for about 20 minutes, diminishing over 60 to 180 minutes. Residual discomfort can last 24 hours.

Ceftriaxone is contraindicated in patients with known hypersensitivity to cephalosporins, penicillins and/or carbapenems.

Long term use of ceftriaxone through intravenous route can cause overgrowth of organisms on the surface of the tongue. Monitoring tongue and oral cavity is recommended.

Warnings

FDA notified healthcare professionals of an update to a previous alert that addresses the interaction of ceftriaxone with calcium-containing products, based on previously reported fatal cases in neonates. At the request of FDA, the manufacturer of ceftriaxone (Roche) conducted two in vitro studies to assess the potential for precipitation of ceftriaxone-calcium when ceftriaxone and calcium-containing products are mixed in vials and in infusion lines. These two in vitro studies were conducted in neonatal and adult plasma to assess the potential for precipitation of ceftriaxone-calcium using varying ceftriaxone and calcium concentrations, including concentrations in excess of those achieved in vivo. Based on the results from these studies, FDA now recommends that ceftriaxone and calcium-containing products may be used concomitantly in patients >28 days of age, using the precautionary recommendations noted because the risk of precipitation is low in this population. F DA had previously recommended, but no longer recommends, that in all age groups ceftriaxone and calcium-containing products should not be administered within 48 hours of one another.


Chemistry

Ceftriaxone is a yellowish-orange crystalline powder which is readily-soluble in water, sparingly soluble in methanol and very slightly soluble in ethanol. The pH of a 1% aqueous solution is approximately 6.7.

The syn-configuration of the methoxyimino moiety confers stability to β-lactamase enzymes produced by many Gram-negative bacteria. Such stability to β-lactamases increases the activity of ceftriaxone against otherwise resistant Gram-negative bacteria. In place of the easily hydrolysed acetyl group of cefotaxime, ceftriaxone has a metabolically-stable thiotriazinedione moiety.

External links


Template:SIB de:Ceftriaxon hu:Ceftriaxon th:เซฟไตรอะโซน

Template:WS